ANI Pharma (ANIP) Tops Q3 EPS by 11c, Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.64, $0.11 better than the analyst estimate of $0.53. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $77.2 million.

GUIDANCE:

ANI Pharma sees FY2022 EPS of $1.34-$1.62, versus the consensus of $1.37. ANI Pharma sees FY2022 revenue of $295-315 million, versus the consensus of $303 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• C.H. Robinson acquires DeSpir Logistics for $75 million